<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:department>Medicine and Biomedical Science</gtr:department><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/49E7A3A0-05EB-419E-ADE6-CE97355D2F28"><gtr:id>49E7A3A0-05EB-419E-ADE6-CE97355D2F28</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Barratt</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CDF99109-6551-4702-82BE-688365A28487"><gtr:id>CDF99109-6551-4702-82BE-688365A28487</gtr:id><gtr:firstName>Harry</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Moore</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C5727FE3-6AB0-4A41-8F96-0657649247D7"><gtr:id>C5727FE3-6AB0-4A41-8F96-0657649247D7</gtr:id><gtr:firstName>K</gtr:firstName><gtr:surname>Martin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C3DC5376-BEE0-4D54-9DA7-45045CD6F71B"><gtr:id>C3DC5376-BEE0-4D54-9DA7-45045CD6F71B</gtr:id><gtr:firstName>Kamal</gtr:firstName><gtr:surname>Ahuja</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4F9094D4-A94D-4474-93A8-32D8F3A6561C"><gtr:id>4F9094D4-A94D-4474-93A8-32D8F3A6561C</gtr:id><gtr:firstName>Charles</gtr:firstName><gtr:surname>Kingsland</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7E03D804-BBE1-4859-972E-F3C1A082D333"><gtr:id>7E03D804-BBE1-4859-972E-F3C1A082D333</gtr:id><gtr:firstName>Masoud</gtr:firstName><gtr:surname>Afnan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A271CEC6-411C-4751-A079-0EF67D8BAA18"><gtr:id>A271CEC6-411C-4751-A079-0EF67D8BAA18</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Kennedy</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C1DF0C94-7231-422A-8C61-C85A8BD4D3EF"><gtr:id>C1DF0C94-7231-422A-8C61-C85A8BD4D3EF</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>Walter</gtr:otherNames><gtr:surname>Andrews</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C0221164-91FF-4073-B443-1B6AE4E4E328"><gtr:id>C0221164-91FF-4073-B443-1B6AE4E4E328</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:otherNames>B</gtr:otherNames><gtr:surname>Fishel</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/433BD83B-360A-453C-8FFD-57D635E732D4"><gtr:id>433BD83B-360A-453C-8FFD-57D635E732D4</gtr:id><gtr:firstName>Geraldine</gtr:firstName><gtr:otherNames>Mary</gtr:otherNames><gtr:surname>Hartshorne</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0CC0E19C-EFEF-45AD-9F1C-55053DF62040"><gtr:id>0CC0E19C-EFEF-45AD-9F1C-55053DF62040</gtr:id><gtr:firstName>W</gtr:firstName><gtr:surname>Ledger</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0300496"><gtr:id>2DCD2EBB-466E-4E73-A38A-B2E0551690E6</gtr:id><gtr:title>A Network for the generation of GMP Stem Cell lines</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0300496</gtr:grantReference><gtr:abstractText>Embryonic stem cells have the capacity to form all the cells of the body. It is therefore possible to produce specific cells in culture which in principle could be used to replace cells lost through degenerative conditions such as Parkinson s disease and diabetes. The long-term potential of stem cells to treat a variety of diseases is immense but the research and technology requires the development of a complex infrastructure. Embryonic stem cell lines are derived from embryos donated for research and surplus to clinical requirement. The formation of a network of assisted conception centres using common procedures and management will enable embryos to used in the most efficient way and to the best ethical standards.</gtr:abstractText><gtr:technicalSummary>Procurement of human embryos donated for research and their judicial use must always be undertaken in a highly responsible and sensitive manner. High quality embryos that can develop into late blastocysts in vitro with good developmental capacity are necessary for reliable generation of human embryonic stem (hES) cell lines. Moreover, hES cell lines for regenerative therapies must comply with good medical/manufacturing practise (GMP). To support and develop the management and research capacity of Assisted Conception Units (ACUs) a network comprising a ?hub? research laboratory (Stem Cell Facility, Academic Unit of Reproductive and Developmental Medicine, University of Sheffield) and ?spokes? of 15 ACUs is proposed. Over 5000 patient cycles per annum (about 17% of cycles in the UK) will be accessed to provide 500 blastocysts p.a. The consortium builds on an existing network providing human embryos that enter an ongoing research programme for derivation and differentiation of hES cells. 
The main objectives of the consortium will be to:
Form a cohesive network with specific and uniform management protocols. 
Coordinate transfer of embryos and the accompanying records between ACUs and research laboratories and provide administrative support centrally and locally.
Develop best practise that ensures provenance of donated embryos can reach the required standard operating procedures for GMP.
Develop embryology/stem cell skills and methods for the most judicious use of embryos donated for stem cell research.
Disseminate information and skills between ACUs, ACUs and hub research laboratory, National Stem Cell Bank, and with patients and general public by having website, workshops and other forums. 

Initially, hES lines will be created for research but a prime objective is to establish the necessary laboratory, protocol, and regulatory structures to start prospective collection of embryos and derive hES cells to reach a GMP accredited standard within 12 months.</gtr:technicalSummary><gtr:fund><gtr:end>2008-05-22</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-05-23</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>308806</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Procedures for producinh embryonic stem cells to GMP</gtr:description><gtr:grantRef>G0300496</gtr:grantRef><gtr:id>711D2790-DA7F-4BA9-AE80-75F0325425FA</gtr:id><gtr:impact>commercial collaborations</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>4CA37898091</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>GMP standard operating procedures</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Commercialisation of stem cells</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>5B479860-3815-432B-9949-554650422830</gtr:id><gtr:impact>input into guidelines related to use of human embryonic stem cells at National level</gtr:impact><gtr:outcomeId>01DCAB2B7DC</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Practical Training for human embryonic stem cells</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>029F7756-3A8C-4208-A781-B74FEB389D28</gtr:id><gtr:impact>Our course format adopted by others</gtr:impact><gtr:outcomeId>3F8425FD6AA</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B8B21277-F0A3-4337-8065-4BEF9D3FD7A6</gtr:id><gtr:title>Genome-wide parent-of-origin DNA methylation analysis reveals the intricacies of human imprinting and suggests a germline methylation-independent mechanism of establishment.</gtr:title><gtr:parentPublicationTitle>Genome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8980d7418afe6acc6a710129d945f845"><gtr:id>8980d7418afe6acc6a710129d945f845</gtr:id><gtr:otherNames>Court F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1088-9051</gtr:issn><gtr:outcomeId>544fa7242de6f3.57968362</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A9D8784-6484-471C-A6A9-602AE34DC7F4</gtr:id><gtr:title>ELF5-enforced transcriptional networks define an epigenetically regulated trophoblast stem cell compartment in the human placenta.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4843181f21764df7133f54d6d304065d"><gtr:id>4843181f21764df7133f54d6d304065d</gtr:id><gtr:otherNames>Hemberger M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>fyz9v61ysHR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC55849E-5C8C-45FD-8C7C-EC49725235CC</gtr:id><gtr:title>Derivation of GMP raw materials for use in regenerative medicine: hESC-based therapies, progress toward clinical application.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/266ce29dfb2d2bb7b3ccbe48fd9b49f8"><gtr:id>266ce29dfb2d2bb7b3ccbe48fd9b49f8</gtr:id><gtr:otherNames>Hewitt ZA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>06ACA5BBC17</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0300496</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>